1 Characteristics and outcomes of clinically diagnosed RT-PCR swab negative COVID-19: a 2 retrospective cohort study Paul Middleton, ^{1*} Pablo N. Perez-Guzman (0000-0002-5277-5196), ^{2*} Alexandra Cheng, ¹ 3 Naveenta Kumar, Mara D. Kont, Anna Daunt, Sujit Mukherjee, Graham Cooke, Timothy 4 B. Hallett, Katharina Hauck, Peter J. White, Mark R. Thursz, Shevanthi Nayagam (0000-5 0002-8030-3380),1,2 6 7 *These first authors contributed equally to this article 8 ¹ Imperial College Healthcare NHS Trust, London, UK (P. Middleton, A. Cheng, N. Kumar, A. Daunt, 9 S. Mukherjee, G. Cooke, M. Thursz, S. Nayagam) ² Imperial College London, London, UK (P. Perez-Guzman, M. Kont, G. Cooke, T. Hallett, K. Hauck, 10 P. White, S. Nayagam) 11 12 **Corresponding Author:** 13 Dr Shevanthi Nayagam, MRC Centre for Global Infectious Disease Analysis Department of 14 Infectious Disease Epidemiology, Faculty of Medicine at St Mary's Campus, Imperial College 15 London, W2 1PG. UK. Email: s.nayagam01@imperial.ac.uk 16 The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions 17 of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated. 18 19 Keywords: COVID-19, RT-PCR-negative, swab-negative, hospitalization outcomes 20 Conflicts of interest: None. 21 Word count for abstract: 254

Running title

Word count for text: 1,637

22

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

COVID-19 swab-negative vs swab-positive cohort UK Keywords Coronavirus infection, COVID-19, severe acute respiratory syndrome coronavirus 2, Retrospective Studies, Cohort Studies, Hospitalization Abstract Patients with strong clinical features of COVID-19 with negative real time polymerase chain reaction (RT-PCR) SARS-CoV-2 testing are not currently included in official statistics. The scale, characteristics and clinical relevance of this group are thus unknown. We performed a retrospective cohort study in two large London hospitals to characterize the demographic, clinical, and hospitalization outcome characteristics of swab-negative clinical COVID-19 patients. We found 1 in 5 patients with a negative swab and clinical suspicion of COVID-19 received a clinical diagnosis of COVID-19 within clinical documentation, discharge summary or death certificate. We compared this group to a similar swab positive cohort and found similar demographic composition, symptomology and laboratory findings. Swab-negative clinical COVID-19 patients had better outcomes, with shorter length of hospital stay, reduced need for >60% supplementary oxygen and reduced mortality. Patients with strong clinical features of COVID-19 that are swab-negative are a common clinical challenge. Health systems must recognize and plan for the management of swab-negative patients in their COVID-19 clinical management, infection control policies and epidemiological assessments. **Background** As of 2nd August 2020, the World Health Organization (WHO) has reported 17.6 million confirmed cases of COVID-19 globally with 532,340 confirmed deaths.[1] WHO defines a confirmed case as a person with laboratory confirmation of COVID-19 infection.[2] Cases where laboratory confirmation is not done or inconclusive are recognized as probable cases however those with strong clinical features, but negative testing are not recognized.[2] Epidemiological evaluations in many countries,

including the UK, focus on patients with positive real-time polymerase chain reaction (RT-PCR)

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

testing.[3] This places a significant importance on the diagnostic accuracy of laboratory testing when it has been performed. However, the diagnostic accuracy of RT-PCR upper respiratory tract swabs is increasingly being questioned. A study utilizing both chest computerized tomography imaging (CT) and RT-PCR testing in patients with suspected COVID-19 found 75% of cases with a negative RT-PCR test had CT findings suggestive of COVID-19.[4] Several case reports describe patients with clinical features of COVID-19 but negative upper respiratory tract swabs who later have positive confirmatory testing on induced sputum or bronchial lavage.[5-7] A recent analysis of published cohorts calculated the falsenegative rate of RT-PCR testing amongst symptomatic COVID-19 patients who eventually test positive for COVID-19 is likely 20% and increases gradually with time since symptoms onset.[8] Acknowledging this, some patients with strong features of COVID-19 receive a clinical diagnosis of COVID-19 despite a negative swab result. This clinical approach is being further recognized in the admission criteria of some clinical trials who permit recruitment of these patients.[9] For example in the recently reported RECOVERY trial 10% of those randomized to dexamethasone had a negative swab at the time of randomization.[10] However, little has been documented about the scale and clinical relevance of this subgroup of patients for whom there is no consensus on optimal management. Our study aims to assess the real-world prevalence and characteristics of clinically diagnosed swab-negative COVID-19, including factors associated with swab-negative disease, and whether their outcomes differ to swab-positive patients. **Methods** We retrospectively reviewed medical admissions from March 1 to April 12, 2020 at Imperial College Healthcare Trust (ICHNT) in London, UK from two admitting sites. We defined eligible cases as those who presented with clinical suspicion of COVID-19 or had symptoms compatible with COVID-19, were admitted to hospital and had a SARS-CoV-2 nasopharyngeal swab performed. We collected full demographic characteristics, time course of symptoms, time of presentation and testing,

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

presenting symptoms, final diagnosis and outcome as well as radiological and laboratory findings for all patients with a negative swab from admission until discharge. Cases were evaluated using the Public Health England (PHE) testing criteria for possible COVID cases. We defined swab-negative clinical COVID-19 cases as follows: a) clinical COVID-19 or high level of suspicion as defined by the treating medical team (as recorded in the medical notes, discharge documents or death certificate); and b) RT-PCR swab-negative (on initial and any subsequent tests performed). The swab-negative clinical COVID-19 group of patients was compared to a subgroup of a previously described swab-positive cohort who were similarly admitted via general medical admissions. 11 Chisquare, Fisher's and rank sum tests were used, as appropriate, to compare the cohorts' characteristics, and odds ratios (OR) calculated to assess differences in the outcomes of respiratory deterioration, defined as requiring greater than 60% oxygen, and death. Lastly, we assessed the cumulative risk of the competing outcomes of hospital discharge and death over time using the using the Nelson-Aelen estimator. The study was approved by the ICHNT clinical governance team. As we report on routinely collected non-identifiable clinical audit data, no individual informed consent was required under the UK policy framework for health and social care. All methods were conducted in accordance with relevant guidelines and regulations. **Results** We identified 1,119 emergency medical admissions with initial clinical suspicion of COVID-19 who had a SARS-CoV-2 swab performed (Figure 1). Initial swab was negative in 456 (41%) and positive in 663 (59%) patients. 62% (281/456) of those who were swab-negative received an alternative diagnosis. 47 of the swab-negative cohort later tested positive for COVID-19 on repeat PCR testing. The most common alternative diagnoses included community acquired pneumonia, lower respiratory

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

tract infection and exacerbations of chronic lung disease such as chronic obstructive pulmonary disease. Overall, 20% (94/456) of swab-negative cases were identified as swab-negative clinical COVID-19. 98% (92/94) of these cases fulfilled PHE criteria for patients eligible to be swabbed for COVID-19 compared to 84% of the entire swab-negative group. 41/94 had repeat swab testing performed and remained negative. The demographic profile and symptomatology of the swab-positive and swab-negative cohorts were similar, with high rates of influenza-like symptoms, cough and fever in both groups (Table). Typical features such as shortness of breath was higher in the swab-negative clinical COVID-19 cohort (75/92 (79.79%) vs 312/478 (66.67%) p=0.017). The swab-negative cohort was more likely to have chest radiographs reporting typical COVID-19 appearances than the swab-positive cohort (53/77 (68.83%) vs 195/389 (50.13%); p=0.004). Overall haematological and biochemical findings that have been associated with COVID-19 including raised CRP, d-dimer and ferritin were similarly distributed between the two cohorts. A higher proportion of patients had moderate lymphopenia within the swab-negative group (65/94 (69.15%) vs 258/460 (56.09%); p=0.026). Patients in the swab-negative group presented slightly later in their clinical course after symptom onset, at a median of 7 days (IQR 4.3-13) for the RT-PCR-negatives compared to 6 days (IQR 3-10) within the RT-PCR-positives cohort (p<0.001). Interestingly, RT-PCR-negative patients had better hospitalisation outcomes than RT-PCR-positives. The former had a 57% lower probability of requiring ≥60% supplementary oxygen during hospitalisation (OR 0.43, 95%CI 0.26-0.70, p<0.001), a shorter length of hospital stay (median 5 days vs 6 days, p<0.001) and 60% lower probability of death (OR 0.40, 95%CI 0.22-0.72, p<0.001). The cumulative risk of being discharged alive was significantly higher in the swab-negative group than the positive group (p < 0.001). Furthermore, the

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

swab-negative cohort have a lower cumulative risk of in-hospital mortality than positives (p<0.001) (Figure 2). Discussion We find one in five patients who had a negative COVID-19 swab received a clinical diagnosis of COVID-19 despite negative testing. This represents a 13% higher estimate of the number of hospitalized COVID-19 patients compared to considering swab-positive patients alone. Overall the clinical, biochemical and radiological features of the swab-negative clinical COVID-19 cohort did not differ significantly to the swab-positive cohort. Typical features of COVID-19 such as shortness of breath, typical chest x-ray findings and lymphopenia are more common in the swab-negative cohort as we would expect in a group defined by these parameters. Despite these similarities, swab-negative patients tended to have a longer delay between symptom onset and hospitalization, and had significantly better hospitalization outcomes, including mortality. Whether this potentially less aggressive phenotype is related to a lower viremia, variations in immune response or a different stage of illness presenting after period of peak viral replication is not yet known. Further research including immunological profiling would help further elucidate underlying disease mechanisms. Our study is, to our knowledge, the first to detail a cohort of swab-negative clinical COVID-19. Our results provide evidence to validate swab-negative COVID-19 as a real clinical entity commonly encountered in hospital settings, findings which have important implications for current clinical practice and public health guidance.[12] Firstly, it highlights that clinicians caring for COVID-19 patients should maintain a high clinical suspicion, even in the presence of a negative swab result. Our results suggest that a combination of clinical, radiological and biochemical features in keeping with COVID-19 disease, rather than swab results alone, should guide clinical management.

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

Secondly, managing swab-negative clinical COVID-19 within hospital poses disease control challenges. Cohorting this group with swab-positive patients presents potential risk of SARS-CoV-2 infection, if the clinical diagnosis is incorrect. 12 Alternatively, isolating these patients from both swabnegative low-risk patients and swab-positive groups would place significant strain on hospital resources and may be unfeasible during an outbreak. Repeated testing may be beneficial in some cases however in our cohort 41/94 swab negative clinical COVID-19 cases had a repeat swab which remained negative. Testing on sputum or bronchial lavage may provide greater sensitivity.⁵⁻⁷ However, their use is limited by feasibility and potential risk to healthcare workers. Serological testing to confirm exposure to SARS-CoV-2 is likely the optimal second-line test as it is not operatordependent, is low-risk to healthcare workers, and can feasibly be performed on a large number of patients. Serological proof of exposure could reduce concern regarding cohorting with swab-positive patients. However, these tests are not yet in routine clinical practice and require further evaluation. Lastly, but importantly, from a public health perspective, swab-negative clinically diagnosed COVID-19 patients may not be captured in surveillance statistics, thereby underestimating healthcare demand. As the pandemic evolves countries with reducing incidence should consider this clinical group and how they should be addressed when planning interventions to prevent second-wave outbreaks such as contact tracing. Our study is limited by its retrospective nature and likely under-estimates the proportion of patients with swab-negative clinical COVID-19, as it requires a high degree of clinical confidence without alternative diagnosis. The lack of positive confirmatory test means we cannot be sure of the true diagnosis in the clinically diagnosed swab negative group. However, this does not detract from the clinical problems this group presents to hospital management and epidemiological assessment. In the absence of improved testing or routine second line testing for patients who have high clinical suspicion of COVID-19 but negative swab testing, this group is likely to continue to pose a clinical challenge. During the period of data collection changes in local policy regarding repeated testing prevented re-testing for COVID-19 even in cases with high clinical suspicion therefore not all patients had repeated testing performed.

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

Patients with strong clinical features of COVID-19 who have negative nasopharyngeal RT-PCR test results are a common but understudied clinical group. Patients with a clinical diagnosis of COVID-19 do not differ significantly to similar swab-positive patients but seem to have better outcomes. Healthcare services should recognize and plan for the management of this group when making disease control interventions and epidemiological assessments. References World Health Organization. Coronavirus disease (COVID-2019) situation reports. 2020.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situationreports (accessed 18 May 2020). World Health Organization. Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance. 2020.https://www.who.int/publications-detail/global-surveillance-for-covid-19-causedby-human-infection-with-covid-19-virus-interim-guidance (accessed 18 May 2020). UK Government. Number of coronavirus (COVID-19) cases and risk in the UK. Number of coronavirus (COVID-19) cases and risk in the UK. 2020.https://www.gov.uk/guidance/coronavirus-covid-19-information-for-the-public (accessed 27 Apr 2020). Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology 2020;:200642. doi:10.1148/radiol.2020200642 Hase R, Kurita T, Muranaka E, et al. A case of imported COVID-19 diagnosed by PCRpositive lower respiratory specimen but with PCR-negative throat swabs. *Infectious* Diseases 2020;**52**:423–6. doi:10.1080/23744235.2020.1744711

215 6 Winichakoon P, Chaiwarith R, Liwsrisakun C, et al. Negative Nasopharyngeal and 216 Oropharyngeal Swabs Do Not Rule Out COVID-19. J Clin Microbiol 2020;58:e00297-217 20, /jcm/58/5/JCM.00297-20.atom. doi:10.1128/JCM.00297-20 218 Han H, Luo Q, Mo F, et al. SARS-CoV-2 RNA more readily detected in induced sputum 219 than in throat swabs of convalescent COVID-19 patients. The Lancet Infectious Diseases 220 2020;:S1473309920301742. doi:10.1016/S1473-3099(20)30174-2 221 Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in False-Negative Rate of 222 Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time 223 Since Exposure. Annals of Internal Medicine 2020;:M20-1495. doi:10.7326/M20-1495 224 Kulkarni S, Fisk M, Kostapanos M, et al. Repurposed immunomodulatory drugs for 225 Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted 226 with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study 227 protocol for a randomised controlled trial. Trials 2020;21:626. doi:10.1186/s13063-020-228 04535-4 229 10 Horby P, Lim WS, Emberson J, et al. Effect of Dexamethasone in Hospitalized Patients 230 with COVID-19: Preliminary Report. Infectious Diseases (except HIV/AIDS) 2020. 231 doi:10.1101/2020.06.22.20137273 232 11 Perez Guzman P, Daunt A, Mukherjee S, et al. Report 17: Clinical characteristics and 233 predictors of outcomes of hospitalised patients with COVID-19 in a London NHS Trust: 234 a retrospective cohort study. Imperial College London 2020. doi:10.25561/78613 235 12 Public Health England. COVID-19: investigation and initial clinical management of 236 possible cases. 2020.https://www.gov.uk/government/publications/wuhan-novel-237 coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-238 management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection#criteria 239 (accessed 18 May 2020).

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

Author Contributions: SN - Conceived study, data interpretation and provided clinical expertise and critical revision of the manuscript for intellectual and scientific content PM – Conceived study, wrote the first manuscript and led on acquisition of data, interpreted data, provided clinical expertise and critical revision of the manuscript for intellectual and scientific content PP – Conceived study, performed statistical analysis, interpreted data, provided clinical expertise and critical revision of the manuscript for intellectual and scientific content AC – Supported data acquisition and curation and critical revision of the manuscript for intellectual and scientific content NK - Supported data acquisition and curation and critical revision of the manuscript for intellectual and scientific content AD - Supported data acquisition and curation and critical revision of the manuscript for intellectual and scientific content SM - Supported data acquisition and curation and critical revision of the manuscript for intellectual and scientific content MDK – Performed statistical analysis, data interpretation and critical revision of the manuscript for intellectual and scientific content GC - Provided clinical expertise and critical revision of the manuscript for intellectual and scientific content MRT – Provided clinical expertise and scientific expertise to lead the discussion of clinical and public health implications and critical revision of the manuscript for intellectual and scientific content PJW - Provided clinical expertise and scientific expertise to lead the discussion of clinical and public health implications and critical revision of the manuscript for intellectual and scientific content

TBH - Provided clinical expertise and scientific expertise to lead the discussion of clinical and public health implications and critical revision of the manuscript for intellectual and scientific content KH - Provided clinical expertise and scientific expertise to lead the discussion of clinical and public health implications and critical revision of the manuscript for intellectual and scientific content **Funding Statement** This work was supported by Medical Research Council Centre for Global Infectious Disease Analysis. Funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. **Competing Interests Statement** Acknowledgements: SN, TBH, KH, PJW and PP are supported by the MRC Centre for Global Infectious Disease Analysis (MR/R015600/1); this award is jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 program supported by the European Union (EU). The authors would also like to acknowledge the support of the Imperial BRC Centre and J-IDEA. The authors would like to thank all patients and staff at Imperial College Healthcare NHS Trust. Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Figure 1. Case identification. *98% (92/94) Clinical COVID-19 cases fulfilled PHE guidance on testing eligibility Figure 2. Cumulative risk of hospitalization outcomes by swab status.

291

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

Table. Description of clinical characteristics and clinical course

- Abbreviations: CK, creatine kinase; CRP, C-reactive protein; EWS, early warning score;
- 295 FiO2, inspiratory fraction of oxygen; IQR, interquartile range; LDH, lactate dehydrogenase.
 - * Pearson's Chi-squared test with Yates' continuity correction
 - †Wilcoxon rank sum test with continuity correction
- [‡] Fisher's exact test for count data

294

296

| Demography Alle, n (%) 288 (61.5%) 57 (60.6%) 0.962 * Median age (IQR) 88 (54 - 79) 67 (54.25 - 78) 0.638 * Symptoms Influenza-like syndrome, n (%) 341 (72.9%) 74 (78.7%) 0.293 * Cough, n (%) 353 (75.4%) 71 (75.5%) 1.000 * Fever, n (%) 389 (83.1%) 75 (79.8%) 0.530 * Nasal discharge, n (%) 9 (1.9%) 3 (3.2%) 0.433 * Shortness of breath, n (%) 312 (66.7%) 75 (79.8%) 0.017 * Wheezing, n (%) 1 (0.2%) 4 (4.3%) 0.003 * Anosmia, n (%) 12 (2.6%) 10 (10.6%) 0.001 * Admission Oxygen Requirements (FiO2) 254 (54.3%) 50 (53.2%) 0.937 * 24 to <40% 108 (23.1%) 31 (33.0%) 0.58 * 40 to <60% 8 (1.7%) 3 (3.2%) 0.405 * *60% 98 (20.9%) 10 (10.6%) 0.030 * Chest Radiograph Normal CXR 195/389 (50.2%) 53/77 (68.8%) 0.04 * | | RT-PCR-positive (n = 468) | RT-PCR-negative (n = 94) | p value |
|---|--------------------------------------|------------------------------|-----------------------------|--------------------|
| Median age (IQR) 68 (54 - 79) 67 (54.25 - 78) 0.638 ¹ Symptoms Cough, n (%) 341 (72.9%) 74 (78.7%) 0.293 ³ Cough, n (%) 353 (75.4%) 71 (75.5%) 1.000 ° Fever, n (%) 389 (83.1%) 75 (79.8%) 0.530 ° Nasal discharge, n (%) 9 (1.9%) 3 (3.2%) 0.433 ¹ Shortness of breath, n (%) 312 (66.7%) 75 (79.8%) 0.017 ° Wheezing, n (%) 1 (0.2%) 4 (4.3%) 0.003 ¹ Anosmia, n (%) 12 (2.6%) 10 (10.6%) 0.001 ° Admission Oxygen Requirements (FIO2) Room air, n (%) 254 (54.3%) 50 (53.2%) 0.937 ° 24 to <40% | Demography | | • | |
| Symptoms Influenza-like syndrome, n (%) 341 (72.9%) 74 (78.7%) 0.293 * Cough, n (%) 353 (75.4%) 71 (75.5%) 1.000 * Fever, n (%) 389 (83.1%) 75 (79.8%) 0.530 * Nasal discharge, n (%) 9 (1.9%) 3 (3.2%) 0.433 * Shortness of breath, n (%) 312 (66.7%) 75 (79.8%) 0.017 * Wheezing, n (%) 1 (0.2%) 4 (4.3%) 0.003 * Anosmia, n (%) 12 (2.6%) 10 (10.6%) 0.001 * Admission Oxygen Requirements (FIO2) Room air, n (%) 254 (54.3%) 50 (53.2%) 0.937 * 24 to <40% | Male, n (%) | 288 (61.5%) | 57 (60.6%) | 0.962 * |
| March Mar | Median age (IQR) | 68 (54 - 79) | 67 (54.25 - 78) | 0.638 [†] |
| Cough, n (%) 353 (75.4%) 71 (75.5%) 1.000 ° Fever, n (%) 389 (83.1%) 75 (79.8%) 0.530 ° Nasal discharge, n (%) 9 (1.9%) 3 (3.2%) 0.433 ° Shortness of breath, n (%) 312 (66.7%) 75 (79.8%) 0.017 ° Wheezing, n (%) 1 (0.2%) 4 (4.3%) 0.003 ° Anosmia, n (%) 12 (2.6%) 10 (10.6%) 0.001 ° Admission Oxygen Requirements (FiO2) 80 10 (10.6%) 0.937 ° Room air, n (%) 254 (54.3%) 50 (53.2%) 0.937 ° 24 to <40% | Symptoms | | | |
| Fever, n (%) 389 (83.1%) 75 (79.8%) 0.530 ° Nasal discharge, n (%) 9 (1.9%) 3 (3.2%) 0.433 ¹ Shortness of breath, n (%) 312 (66.7%) 75 (79.8%) 0.017 ° Wheezing, n (%) 1 (0.2%) 4 (4.3%) 0.003 ¹ Anosmia, n (%) 12 (2.6%) 10 (10.6%) 0.001 ° Admission Oxygen Requirements (FiO2) 8 (2.6%) 50 (53.2%) 0.937 ° Room air, n (%) 254 (54.3%) 50 (53.2%) 0.937 ° 24 to <40% 108 (23.1%) 31 (33.0%) 0.058 ° 40 to <60% 8 (1.7%) 3 (3.2%) 0.405 ° >60% 98 (20.9%) 10 (10.6%) 0.030 ° Chest Radiograph Normal CXR 65/389 (16.7%) 7/77 (9.1%) 0.129 ° Typical COVID-19 CXR 195/389 (50.2%) 53/77 (68.8%) 0.004 ° Attypical COVID-19 CXR 106/389 (27.3%) 15/77 (19.5%) 0.201 ° Lymphocytes ≥1.1 154/460 (33.5%) 25 (26.6%) 0.238 ° Lymphocytes ≥2.1. 154/460 (33.5%) | Influenza-like syndrome, n (%) | 341 (72.9%) | 74 (78.7%) | 0.293 * |
| Nasal discharge, n (%) 9 (1.9%) 3 (3.2%) 0.433 [‡] Shortness of breath, n (%) 312 (66.7%) 75 (79.8%) 0.017 [*] Wheezing, n (%) 1 (0.2%) 4 (4.3%) 0.003 [‡] Anosmia, n (%) 12 (2.6%) 10 (10.6%) 0.001 [*] Admission Oxygen Requirements (FiO2) Room air, n (%) 254 (54.3%) 50 (53.2%) 0.937 [*] 24 to <40% 108 (23.1%) 31 (33.0%) 0.058 [*] 40 to <60% 8 (1.7%) 3 (3.2%) 0.405 [‡] >60% 98 (20.9%) 10 (10.6%) 0.030 [*] Chest Radiograph Normal CXR 65/389 (16.7%) 7/77 (9.1%) 0.129 [*] Typical COVID-19 CXR 195/389 (50.2%) 53/77 (68.8%) 0.004 [*] Atypical COVID-19 CXR 106/389 (27.3%) 15/77 (19.5%) 0.201 [*] Non-COVID abnormal CXR 23/389 (5.9%) 2/77 (2.6%) 0.403 [‡] Laboratory Test Lymphocytes ≥1.1 154/460 (33.5%) 25 (26.6%) 0.238 [*] Lymphocytes 0.5-1.0 258/460 (56.1%) 65 (69.2%) 0.026 [*] Lymphocytes <0.5 43/460 (9.4%) 4 (4.3%) 0.152 [‡] CRP ≥100 230/448 (51.3%) 55/93 (59.1%) 0.209 [*] CRP 10-99 186/448 (41.5%) 33/93 (35.5%) 0.336 [*] CRP <10 32/448 (7.1%) 5/93 (5.4%) 0.698 [*] D-dimer ≥3000 42/225 (18.7%) 16/66 (24.2%) 0.411 [*] | Cough, n (%) | 353 (75.4%) | 71 (75.5%) | 1.000 * |
| Shortness of breath, n (%) 312 (66.7%) 75 (79.8%) 0.017 * Wheezing, n (%) 1 (0.2%) 4 (4.3%) 0.003 * Anosmia, n (%) 12 (2.6%) 10 (10.6%) 0.001 * Admission Oxygen Requirements (FiO2) Room air, n (%) 254 (54.3%) 50 (53.2%) 0.937 * 24 to <40% | Fever, n (%) | 389 (83.1%) | 75 (79.8%) | 0.530 * |
| Wheezing, n (%) 1 (0.2%) 4 (4.3%) 0.003 [†] Anosmia, n (%) 12 (2.6%) 10 (10.6%) 0.001 [*] Admission Oxygen Requirements (FiO2) Room air, n (%) 254 (54.3%) 50 (53.2%) 0.937 [*] 24 to <40% | Nasal discharge, n (%) | 9 (1.9%) | 3 (3.2%) | 0.433 ‡ |
| Anosmia, n (%) Admission Oxygen Requirements (FiO2) Room air, n (%) 254 (54.3%) 50 (53.2%) 0.937 * 24 to <40% 108 (23.1%) 31 (33.0%) 0.058 * 40 to <60% 8 (1.7%) 3 (3.2%) 0.405 ‡ >60% 98 (20.9%) 10 (10.6%) 0.030 * Chest Radiograph Normal CXR 65/389 (16.7%) 7/77 (9.1%) 0.129 * Typical COVID-19 CXR 195/389 (50.2%) 53/77 (68.8%) 0.004 * Atypical COVID-19 CXR 106/389 (27.3%) 15/77 (19.5%) 0.201 * Non-COVID abnormal CXR 23/389 (5.9%) 2777 (2.6%) 0.403 ‡ Lymphocytes ≥1.1 154/460 (33.5%) 25 (26.6%) 0.238 * Lymphocytes ≥0.5-1.0 258/460 (56.1%) 65 (69.2%) 0.026 * Lymphocytes <0.5 43/460 (9.4%) 4 (4.3%) 0.152 ‡ CRP ≥100 230/448 (51.3%) 55/93 (59.1%) 0.209 * CRP <10 32/448 (7.1%) 5/93 (5.4%) 0.698 * D-dimer ≥3000 42/225 (18.7%) 16/66 (24.2%) 0.411 * | Shortness of breath, n (%) | 312 (66.7%) | 75 (79.8%) | 0.017 * |
| Admission Oxygen Requirements (FiO2) Room air, n (%) 254 (54.3%) 50 (53.2%) 0.937 * 24 to <40% | Wheezing, n (%) | 1 (0.2%) | 4 (4.3%) | 0.003 [‡] |
| Room air, n (%) 254 (54.3%) 50 (53.2%) 0.937 * 24 to <40% | Anosmia, n (%) | 12 (2.6%) | 10 (10.6%) | 0.001 * |
| 24 to <40% 108 (23.1%) 31 (33.0%) 0.058 * 40 to <60% 8 (1.7%) 3 (3.2%) 0.405 ‡ >60% 98 (20.9%) 10 (10.6%) 0.030 * Chest Radiograph Normal CXR 65/389 (16.7%) 7/77 (9.1%) 0.129 * Typical COVID-19 CXR 195/389 (50.2%) 53/77 (68.8%) 0.004 * Atypical COVID-19 CXR 106/389 (27.3%) 15/77 (19.5%) 0.201 * Non-COVID abnormal CXR 23/389 (5.9%) 2/77 (2.6%) 0.403 ‡ Laboratory Test Lymphocytes ≥1.1 154/460 (33.5%) 25 (26.6%) 0.238 * Lymphocytes <0.5 43/460 (9.4%) 4 (4.3%) 0.152 ‡ CRP ≥100 230/448 (51.3%) 55/93 (59.1%) 0.209 * CRP 10-99 186/448 (41.5%) 33/93 (35.5%) 0.336 * CRP <10 32/448 (7.1%) 5/93 (5.4%) 0.698 * D-dimer ≥3000 42/225 (18.7%) 16/66 (24.2%) 0.411 * | Admission Oxygen Requirements (FiO2) | | | |
| 40 to <60% 8 (1.7%) 3 (3.2%) 0.405 [‡] >60% 98 (20.9%) 10 (10.6%) 0.030 * Chest Radiograph Normal CXR 65/389 (16.7%) 7/77 (9.1%) 0.129 * Typical COVID-19 CXR 195/389 (50.2%) 53/77 (68.8%) 0.004 * Atypical COVID-19 CXR 106/389 (27.3%) 15/77 (19.5%) 0.201 * Non-COVID abnormal CXR 23/389 (5.9%) 2/77 (2.6%) 0.403 [‡] Laboratory Test Lymphocytes ≥1.1 154/460 (33.5%) 25 (26.6%) 0.238 * Lymphocytes 0.5-1.0 258/460 (56.1%) 65 (69.2%) 0.026 * Lymphocytes <0.5 43/460 (9.4%) 4 (4.3%) 0.152 [‡] CRP ≥100 230/448 (51.3%) 55/93 (59.1%) 0.209 * CRP 10-99 186/448 (41.5%) 33/93 (35.5%) 0.336 * CRP <10 32/448 (7.1%) 5/93 (5.4%) 0.698 * D-dimer ≥3000 42/225 (18.7%) 16/66 (24.2%) 0.411 * | Room air, n (%) | 254 (54.3%) | 50 (53.2%) | 0.937 * |
| >60% 98 (20.9%) 10 (10.6%) 0.030 * Chest Radiograph Normal CXR 65/389 (16.7%) 7/77 (9.1%) 0.129 * Typical COVID-19 CXR 195/389 (50.2%) 53/77 (68.8%) 0.004 * Atypical COVID-19 CXR 106/389 (27.3%) 15/77 (19.5%) 0.201 * Non-COVID abnormal CXR 23/389 (5.9%) 2/77 (2.6%) 0.403 ‡ Laboratory Test Lymphocytes ≥1.1 154/460 (33.5%) 25 (26.6%) 0.238 * Lymphocytes 0.5-1.0 258/460 (56.1%) 65 (69.2%) 0.026 * Lymphocytes <0.5 43/460 (9.4%) 4 (4.3%) 0.152 ‡ CRP ≥100 230/448 (51.3%) 55/93 (59.1%) 0.209 * CRP 10-99 186/448 (41.5%) 33/93 (35.5%) 0.336 * CRP <10 32/448 (7.1%) 5/93 (5.4%) 0.698 * D-dimer ≥3000 42/225 (18.7%) 16/66 (24.2%) 0.411 * | 24 to <40% | 108 (23.1%) | 31 (33.0%) | 0.058 * |
| Chest Radiograph Normal CXR 65/389 (16.7%) 7/77 (9.1%) 0.129 * Typical COVID-19 CXR 195/389 (50.2%) 53/77 (68.8%) 0.004 * Atypical COVID-19 CXR 106/389 (27.3%) 15/77 (19.5%) 0.201 * Non-COVID abnormal CXR 23/389 (5.9%) 2/77 (2.6%) 0.403 * Laboratory Test Lymphocytes ≥1.1 154/460 (33.5%) 25 (26.6%) 0.238 * Lymphocytes 0.5-1.0 258/460 (56.1%) 65 (69.2%) 0.026 * Lymphocytes <0.5 | 40 to <60% | 8 (1.7%) | 3 (3.2%) | 0.405 [‡] |
| Normal CXR 65/389 (16.7%) 7/77 (9.1%) 0.129 * Typical COVID-19 CXR 195/389 (50.2%) 53/77 (68.8%) 0.004 * Atypical COVID-19 CXR 106/389 (27.3%) 15/77 (19.5%) 0.201 * Non-COVID abnormal CXR 23/389 (5.9%) 2/77 (2.6%) 0.403 ‡ Laboratory Test Lymphocytes ≥1.1 154/460 (33.5%) 25 (26.6%) 0.238 * Lymphocytes 0.5-1.0 258/460 (56.1%) 65 (69.2%) 0.026 * Lymphocytes <0.5 43/460 (9.4%) 4 (4.3%) 0.152 ‡ CRP ≥100 230/448 (51.3%) 55/93 (59.1%) 0.209 * CRP 10-99 186/448 (41.5%) 33/93 (35.5%) 0.336 * CRP <10 32/448 (7.1%) 5/93 (5.4%) 0.698 * D-dimer ≥3000 42/225 (18.7%) 16/66 (24.2%) 0.411 * | >60% | 98 (20.9%) | 10 (10.6%) | 0.030 * |
| Typical COVID-19 CXR 195/389 (50.2%) 53/77 (68.8%) 0.004 * Atypical COVID-19 CXR 106/389 (27.3%) 15/77 (19.5%) 0.201 * Non-COVID abnormal CXR 23/389 (5.9%) 2/77 (2.6%) 0.403 ‡ Laboratory Test Lymphocytes ≥1.1 154/460 (33.5%) 25 (26.6%) 0.238 * Lymphocytes 0.5-1.0 258/460 (56.1%) 65 (69.2%) 0.026 * Lymphocytes <0.5 43/460 (9.4%) 4 (4.3%) 0.152 ‡ CRP ≥100 230/448 (51.3%) 55/93 (59.1%) 0.209 * CRP 10-99 186/448 (41.5%) 33/93 (35.5%) 0.336 * CRP <10 32/448 (7.1%) 5/93 (5.4%) 0.698 * D-dimer ≥3000 42/225 (18.7%) 16/66 (24.2%) 0.411 * | Chest Radiograph | | | |
| Atypical COVID-19 CXR 106/389 (27.3%) 15/77 (19.5%) 0.201 * Non-COVID abnormal CXR 23/389 (5.9%) 2/77 (2.6%) 0.403 ‡ Laboratory Test Lymphocytes ≥1.1 154/460 (33.5%) 25 (26.6%) 0.238 * Lymphocytes 0.5-1.0 258/460 (56.1%) 65 (69.2%) 0.026 * Lymphocytes <0.5 43/460 (9.4%) 4 (4.3%) 0.152 ‡ CRP ≥100 230/448 (51.3%) 55/93 (59.1%) 0.209 * CRP 10-99 186/448 (41.5%) 33/93 (35.5%) 0.336 * CRP <10 32/448 (7.1%) 5/93 (5.4%) 0.698 * D-dimer ≥3000 42/225 (18.7%) 16/66 (24.2%) 0.411 * | Normal CXR | 65/389 (16.7%) | 7/77 (9.1%) | 0.129 * |
| Non-COVID abnormal CXR 23/389 (5.9%) 2/77 (2.6%) 0.403 [‡] Laboratory Test Lymphocytes ≥1.1 154/460 (33.5%) 25 (26.6%) 0.238 * Lymphocytes 0.5-1.0 258/460 (56.1%) 65 (69.2%) 0.026 * Lymphocytes <0.5 43/460 (9.4%) 4 (4.3%) 0.152 [‡] CRP ≥100 230/448 (51.3%) 55/93 (59.1%) 0.209 * CRP 10-99 186/448 (41.5%) 33/93 (35.5%) 0.336 * CRP <10 32/448 (7.1%) 5/93 (5.4%) 0.698 * D-dimer ≥3000 42/225 (18.7%) 16/66 (24.2%) 0.411 * | Typical COVID-19 CXR | 195/389 (50.2%) | 53/77 (68.8%) | 0.004 * |
| Laboratory Test Lymphocytes ≥1.1 154/460 (33.5%) 25 (26.6%) 0.238 * Lymphocytes 0.5-1.0 258/460 (56.1%) 65 (69.2%) 0.026 * Lymphocytes <0.5 | Atypical COVID-19 CXR | 106/389 (27.3%) | 15/77 (19.5%) | 0.201 * |
| Lymphocytes ≥1.1 154/460 (33.5%) 25 (26.6%) 0.238 * Lymphocytes 0.5-1.0 258/460 (56.1%) 65 (69.2%) 0.026 * Lymphocytes <0.5 | Non-COVID abnormal CXR | 23/389 (5.9%) | 2/77 (2.6%) | 0.403 [‡] |
| Lymphocytes 0.5-1.0 258/460 (56.1%) 65 (69.2%) 0.026 * Lymphocytes <0.5 | Laboratory Test | | | |
| Lymphocytes <0.5 43/460 (9.4%) 4 (4.3%) 0.152 [‡] CRP ≥100 230/448 (51.3%) 55/93 (59.1%) 0.209 * CRP 10-99 186/448 (41.5%) 33/93 (35.5%) 0.336 * CRP <10 | Lymphocytes ≥1.1 | 154/460 (33.5%) | 25 (26.6%) | 0.238 * |
| CRP ≥100 230/448 (51.3%) 55/93 (59.1%) 0.209 * CRP 10-99 186/448 (41.5%) 33/93 (35.5%) 0.336 * CRP <10 | Lymphocytes 0.5-1.0 | 258/460 (56.1%) | 65 (69.2%) | 0.026 * |
| CRP 10-99 186/448 (41.5%) 33/93 (35.5%) 0.336 * CRP <10 | Lymphocytes <0.5 | 43/460 (9.4%) | 4 (4.3%) | 0.152 [‡] |
| CRP <10 32/448 (7.1%) 5/93 (5.4%) 0.698 * D-dimer ≥3000 42/225 (18.7%) 16/66 (24.2%) 0.411 * | CRP ≥100 | 230/448 (51.3%) | 55/93 (59.1%) | 0.209 * |
| D-dimer ≥3000 42/225 (18.7%) 16/66 (24.2%) 0.411 * | CRP 10-99 | 186/448 (41.5%) | 33/93 (35.5%) | 0.336 * |
| | CRP <10 | 32/448 (7.1%) | 5/93 (5.4%) | 0.698 * |
| D-dimer 2000-2999 29/225 (12.9%) 9/66 (13.6%) 1.000 * | D-dimer ≥3000 | 42/225 (18.7%) | 16/66 (24.2%) | 0.411 * |
| | D-dimer 2000-2999 | 29/225 (12.9%) | 9/66 (13.6%) | 1.000 * |

| D-dimer 1000-1999 | 64/225 (28.4%) | 19/66 (28.8%) | 1.000 * |
|--------------------------------------|-----------------|---------------|---------------------|
| D-dimer 500-999 | 63/225 (28.0%) | 18/66 (27.3%) | 1.000 * |
| D-dimer <500 | 27/225 (12.0%) | 4/66 (6.1%) | 0.255 [‡] |
| LDH ≥243 | 166/179 (92.7%) | 48/51 (94.1%) | 0.976 * |
| LDH <243 | 13/179 (7.3%) | 3/51 (5.9%) | 1.000 ‡ |
| CK ≥320 | 63/210 (30.0%) | 16/64 (25.0%) | 0.538 * |
| CK <320 | 147/210 (70.0%) | 48/64 (75.0%) | 0.538 * |
| Ferritin ≥5000 | 13/259 (5.0%) | 4/68 (5.9%) | 0.761 [‡] |
| Ferritin 1000-4999 | 94/259 (36.3%) | 27/68 (39.7%) | 0.706 * |
| Ferritin 500-999 | 73/259 (28.2%) | 15/68 (22.1%) | 0.390 * |
| Ferritin 300-499 | 38/259 (14.7%) | 10/68 (14.7%) | 1.000 * |
| Ferritin <300 | 41/259 (15.8%) | 12/68 (17.7%) | 0.860 * |
| Clinical Course | | | |
| Median (IQR) days prior to admission | 6 (3 - 10) | 7 (4.25 - 13) | 0.013 [†] |
| Median (IQR) length of stay | 6 (4 - 10) | 5 (2.25 - 6) | <0.001 [†] |
| Received ≥60% FiO2, n (%) | 215 (45.9%) | 25 (26.6%) | 0.001 * |
| Died, n (%) | 151 (32.3%) | 15 (16.0%) | 0.002 * |
| | | | |



